|
1
|
Landgraeber S, Putz S, Schlattjan M,
Bechmann LP, Totsch M, Grabellus F, Hilken G, Jager M and Canbay A:
Adiponectin attenuates osteolysis in aseptic loosening of total hip
replacements. Acta Biomater. 10:384–393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang H, Xu Y, Zhu M, Gu Y, Zhang W, Shao
H, Wang Y, Ping Z, Hu X, Wang L and Geng D: Inhibition of
titanium-particle-induced inflammatory osteolysis after local
administration of dopamine and suppression of osteoclastogenesis
via D2-like receptor signaling pathway. Biomaterials. 80:1–10.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu S, Virdi AS, Sena K and Sumner DR:
Sclerostin antibody prevents particle-induced implant loosening by
stimulating bone formation and inhibiting bone resorption in a rat
model. Arthritis Rheum. 64:4012–4020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reginster JY, Brandi ML, Cannata-Andia J,
Cooper C, Cortet B, Feron JM, Genant H, Palacios S, Ringe JD and
Rizzoli R: The position of strontium ranelate in today's management
of osteoporosis. Osteoporos Int. 26:1667–1671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karakan NC, Akpinar A, Göze F and Poyraz
Ö: Investigating the effects of systemically administered strontium
ranelate on alveolar bone loss histomorphometrically and
histopathologically on experimental periodontitis in rats. J
Periodontol. 88:e24–e31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rybchyn MS, Slater M, Conigrave AD and
Mason RS: An Akt-dependent increase in canonical Wnt signaling and
a decrease in sclerostin protein levels are involved in strontium
ranelate-induced osteogenic effects in human osteoblasts. J Biol
Chem. 286:23771–23779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferreira E, Bortolin RH, Freire-Neto FP,
Souza KSC, Bezerra JF, Ururahy MAG, Ramos AMO, Himelfarb ST, Abreu
BJ, Didone TVN, et al: Zinc supplementation reduces RANKL/OPG ratio
and prevents bone architecture alterations in ovariectomized and
type 1 diabetic rats. Nutr Res. 40:48–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xiong J and O'Brien CA: Osteocyte RANKL:
New insights into the control of bone remodeling. J Bone Miner Res.
27:499–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wong BR, Josien R, Lee SY, Vologodskaia M,
Steinman RM and Choi Y: The TRAF family of signal transducers
mediates NF-kappaB activation by the trance TRANCE receptor. J Biol
Chem. 273:28355–28359. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yasuda H, Shima N, Nakagawa N, Mochizuki
SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et
al: Identity of osteoclastogenesis inhibitory factor (OCIF) and
osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits
osteoclastogenesis in vitro. Endocrinology. 139:1329–1337. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang H, Jia T, Zacharias N, Gong W, Du HX,
Wooley PH and Yang SY: Combination gene therapy targeting on
interleukin-1β and RANKL for wear debris-induced aseptic loosening.
Gene Ther. 20:128–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakagawa N, Kinosaki M, Yamaguchi K, Shima
N, Yasuda H, Yano K, Morinaga T and Higashio K: RANK is the
essential signaling receptor for osteoclast differentiation factor
in osteoclastogenesis. Biochem Bioph Res Commun. 253:395–400. 1998.
View Article : Google Scholar
|
|
13
|
Hofbauer LC and Schoppet M: Clinical
implications of the osteoprotegerin/RANKL/RANK system for bone and
vascular diseases. JAMA. 292:490–495. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katsuyama H, Otsuki T, Tomita M, Fukunaga
M, Fukunaga T, Suzuki N, Saijoh K, Fushimi S and Sunami S:
Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL
and RANK in osteoblastic MC3T3E1 cells. Int J Mol Med. 15:231–236.
2005.PubMed/NCBI
|
|
15
|
Mamolini E, Cervellati C, Greco P,
Carrieri A, Massari L, Crivellari I, Scapoli C and Bonaccorsi G:
VDR, RANKL and OPG polymorphisms as possible predisposing cofactors
of postmenopausal osteoporosis: Explorative study in Italian
population. Gynecol Endocrinol. 33:937–941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chakravarti A, Marceau AA, Flamand L and
Poubelle PE: Normal human primary CD4+ T lymphocytes synthesize and
release functional osteoprotegerin in vitro. Lab Invest.
88:171–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsuzaki K, Udagawa N, Takahashi N,
Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y,
Higashio K and Suda T: Osteoclast differentiation factor (ODF)
induces osteoclast-like cell formation in human peripheral blood
mononuclear cell cultures. Biochem Bioph Res Commun. 246:199–204.
1998. View Article : Google Scholar
|
|
18
|
Theoleyre S, Wittrant Y, Tat SK, Fortun Y,
Redini F and Heymann D: The molecular triad OPG/RANK/RANKL:
Involvement in the orchestration of pathophysiological bone
remodeling. Cytokine Growth Factor Rev. 15:457–475. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Z, Ding L, Zhang S, Jiang T, Yang Y
and Li R: Effects of icariin on the regulation of the
OPG-RANKL-RANK system are mediated through the MAPK pathways in
IL-1β-stimulated human SW1353 chondrosarcoma cells. Int J Mol Med.
34:1720–1726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang S, Yu H, Gong W, Wu B, Mayton L,
Costello R and Wooley PH: Murine model of prosthesis failure for
the long-term study of aseptic loosening. J Orthop Res. 25:603–611.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo H, Zhang J, Hao S and Jin Q:
Adenovirus-mediated small interfering RNA targeting tumor necrosis
factor-α inhibits titanium particle-induced osteoclastogenesis and
bone resorption. Int J Mol Med. 32:296–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bourne RB, Laskin RS and Guerin JS:
Ten-year results of the first 100 genesis II total knee replacement
procedures. Orthopedics. 30 8 Suppl:S83–S85. 2007.
|
|
24
|
Harato K, Bourne RB, Victor J, Snyder M,
Hart J and Ries MD: Midterm comparison of posterior
cruciate-retaining versus-substituting total knee arthroplasty
using the genesis II prosthesis. A multicenter prospective
randomized clinical trial. Knee. 15:217–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meding JB, Galley MR and Ritter MA: High
survival of uncemented proximally porous-coated titanium alloy
femoral stems in osteoporotic bone. Clin Orthop Relat Res.
468:441–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu X, Zhu S, Cui J, Shao H, Zhang W, Yang
H, Xu Y, Geng D and Yu L: Strontium ranelate inhibits
titanium-particle-induced osteolysis by restraining inflammatory
osteoclastogenesis in vivo. Acta Biomater. 10:4912–4918. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu YC, Chang TK, Yeh ST, Fang HW, Lin CY,
Hsu LI and Huang CH and Huang CH: The potential role of strontium
ranelate in treating particle-induced osteolysis. Acta Biomater.
20:147–154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang T, Yu H, Gong W, Zhang L, Jia T,
Wooley PH and Yang SY: The effect of osteoprotegerin gene
modification on wear debris-induced osteolysis in a murine model of
knee prosthesis failure. Biomaterials. 30:6102–6108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lacey DL, Timms E, Tan HL, Kelley MJ,
Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
et al: Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell. 93:165–176. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park K, Ju WC, Yeo JH, Kim JY, Seo HS,
Uchida Y and Cho Y: Increased OPG/RANKL ratio in the conditioned
medium of soybean-treated osteoblasts suppresses RANKL-induced
osteoclast differentiation. Int J Mol Med. 33:178–184. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song R, Gu J, Liu X, Zhu J, Wang Q, Gao Q,
Zhang J, Cheng L, Tong X, Qi X, et al: Inhibition of osteoclast
bone resorption activity through osteoprotegerin-induced damage of
the sealing zone. Int J Mol Med. 34:856–862. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi
K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A,
et al: Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:pp.
3597–3602. 1998; View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Atkins GJ, Kostakis P, Pan B, Farrugia A,
Gronthos S, Evdokiou A, Harrison K, Findlay DM and Zannettino AC:
RANKL expression is related to the differentiation state of human
osteoblasts. J Bone Miner Res. 18:1088–1098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grimaud E, Soubigou L, Couillaud S,
Coipeau P, Moreau A, Passuti N, Gouin F, Redini F and Heymann D:
Receptor activator of nuclear factor kappaB ligand
(RANKL)/osteoprotegerin (OPG) ratio is increased in severe
osteolysis. Am J Pathol. 163:2021–2031. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Holding CA, Findlay DM, Stamenkov R, Neale
SD, Lucas H, Dharmapatni AS, Callary SA, Shrestha KR, Atkins GJ,
Howie DW and Haynes DR: The correlation of RANK, RANKL and TNFalpha
expression with bone loss volume and polyethylene wear debris
around hip implants. Biomaterials. 27:5212–5219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ndip A, Williams A, Jude EB,
Serracino-Inglott F, Richardson S, Smyth JV, Boulton AJ and
Alexander MY: The RANKL/RANK/OPG signaling pathway mediates medial
arterial calcification in diabetic charcot neuroarthropathy.
Diabetes. 60:2187–2196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang
S, Lu Q and Sun Y: Differential expression of the RANKL/RANK/OPG
system is associated with bone metastasis in human non-small cell
lung cancer. PLoS One. 8:e583612013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Balsa JA, Lafuente C, Gomez-Martin JM,
Galindo J, Peromingo R, Garcia-Moreno F, Rodriguez-Velasco G,
Martinez-Botas J, Gomez-Coronado D, Escobar-Morreale HF, et al: The
role of serum osteoprotegerin and receptor-activator of nuclear
factor-κB ligand in metabolic bone disease of women after obesity
surgery. J Bone Miner Metab. 34:655–661. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stuss M, Sewerynek E, Król I, Stępień-Kłos
W and Jędrzejczyk S: Assessment of OPG, RANKL, bone turnover
markers serum levels and BMD after treatment with strontium
ranelate and ibandronate in patients with postmenopausal
osteoporosis. Endokrynol Pol. 67:174–184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee HY, Shen MX, Lim YL, Tay YK, Chan MM,
Pang SM, Xiao ZW, Ang SB and Ren EC: Increased risk of strontium
ranelate-related SJS/TEN is associated with HLA. Osteoporos Int.
27:2577–2583. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rossini M, Adami G, Adami S, Viapiana O
and Gatti D: Safety issues and adverse reactions with osteoporosis
management. Expert Opin Drug Saf. 15:321–332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo X, Wei S, Lu M, Shao Z, Lu J, Xia L,
Lin K and Zou D: Dose-dependent effects of strontium ranelate on
ovariectomy rat bone marrow mesenchymal stem cells and human
umbilical vein endothelial cells. Int J Biol Sci. 12:1511–1522.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gu Z, Huang B, Li Y, Tian M, Li L and Yu
X: Strontium-doped calcium polyphosphate/ultrahigh molecular weight
polyethylene composites: A new class of artificial joint components
with enhanced biological efficacy to aseptic loosening. Mater Sci
Eng C Mater Biol Appl. 61:526–533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tian A, Zhai JJ, Peng Y, Zhang L, Teng MH,
Liao J, Sun X and Liang X: Osteoblast response to titanium surfaces
coated with strontium ranelate-loaded chitosan film. Int J Oral
Maxillofac Implants. 29:1446–1453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Newman SD, Lotfibakhshaiesh N, O'Donnell
M, Walboomers XF, Horwood N, Jansen JA, Amis AA, Cobb JP and
Stevens MM: Enhanced osseous implant fixation with
strontium-substituted bioactive glass coating. Tissue Eng Part A.
20:1850–1857. 2014. View Article : Google Scholar : PubMed/NCBI
|
